DarioHealth, a digital chronic condition management platform, announced the integration of Twill’s condition-specific communities and peer groups with customized navigation expertise into its cardiometabolic platform.
DarioHealth acquired digital therapeutics company Twill in February, accompanied by a $22.4 million equity financing.
The integration expands on Dario’s holistic approach to managing chronic conditions including diabetes, hypertension and weight management, and aims to boost member engagement and improve health outcomes.
The enhanced features will allow Dario members to join peer-to-peer condition groups, interact with health care experts for advice and access customized educational content.
“There is no single standard of care for every chronic health condition that will work across the diversity of members on Dario’s platform” Keren Zimmerman, chief product officer at Dario, said in a statement.
“That’s why we are constantly assessing clinical evidence and behavioral engagement data to continuously enhance the way we support our members. The new enhancements provide an element that many people need in order to achieve better results.”
______________________________________________________________________
Navamedic, a Nordic pharma company, is partnering with Alex Therapeutics, a digital health provider of disease and drug companion apps, to help in Parkinson’s treatment management.
Alex Therapeutics’ app will support patients on Flexilev (mini tablets of levodopa/carbidopa), a prescription drug to treat Parkinson’s disease.
According to the company, the app provides medication management support that targets the needs and challenges of people with Parkinson’s disease and complements the dose dispenser, OraFID (a mini tablet dispenser) that contains Flexilev.
“We are excited to collaborate with Alex Therapeutics to enhance the lives of Parkinson’s patients through the companion app,” Kathrine Gamborg Andreassen, chief executive officer of Navamedic, said in a statement.
“This partnership not only reflects our commitment to making the treatment more accessible and manageable, but also underscores our dedication to easing the burden that patients face in their day-to-day care.”
______________________________________________________________________
Mobile Health Consumer, a digital health and well-being solutions provider, announced the launch of two programs: GLP-1 Prerequisite Program and GLP-1 Lifestyle Support Program. Both programs aim to foster healthier lifestyle habits before, during and after medication use.
GLP-1 is a class of medications used to treat type 2 diabetes mellitus and obesity.
Mobile Health’s programs provide holistic support that aim to augment the efficacy of medications with the goal of reducing long-term healthcare expenses.
Program number one is the digital GLP-1 Prerequisite Program, building a Foundation for Success, provides employees with knowledge about nutrition, physical activity and sustainable lifestyle changes prior to starting GLP-1 medication.
Employees can also integrate wearable devices, Bluetooth scales, activity trackers and health data into the program, and it offers customized weight management, nutrition and fitness education and mental health support.
The second one is the digital GLP-1 Life Support Program provides tools to employees throughout and after their GLP-1 treatment highlighting the significance of sustained lifestyle style changes.
Employees can integrate wearable devices, Bluetooth scales, activity trackers, and health data into that program as well.
“GLP-1 medications offer a powerful tool in the fight against obesity and related chronic conditions, but true success goes beyond the medication alone,” John Halloran, chief executive officer of Mobile Health Consumer, said in a statement.
“Our programs ensure that employees not only prepare their bodies for GLP-1 treatments with proper weight management and lifestyle education, but also maintain healthy habits long after the medication has ended.”
